EROWYND
Live / Applied — First extension granted (statement of use) (as of 25 Mar 2026)
What this means for you
Not registered yet, but its 14 Feb 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99042199
- Mark type
- Stylized text
- Filed
- 14 Feb 2025
- Published for opposition
- 26 Aug 2025
- Attorney of record
- Xiomara Triana
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; antivirals; antibodies for medical purposes; biological preparations for the treatment of cancer; anticoagulants; stem cells for medical purposes; radio-pharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radio-pharmaceutical preparations; diagnostic preparations for medical purposes
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, Princeton, NJ, US
Prosecution history
- 26 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Mar 2026 — SOU EXTENSION 1 GRANTED
- 25 Mar 2026 — SOU EXTENSION 1 FILED
- 25 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 21 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Aug 2025 — PUBLISHED FOR OPPOSITION
- 20 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Jul 2025 — ASSIGNED TO EXAMINER
- 14 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 14 Feb 2025 — APPLICATION FILING RECEIPT MAILED
- 14 Feb 2025 — NEW APPLICATION ENTERED